How Twin works, step by step.

Step 1

Define the pathway

The treating oncologist selects the relevant Twin route — Blood 600 for blood cancers, or Exome WES, Liquid 523 or Tissue 335 for solid tumours — and confirms the sample and test scope. The choice depends on the clinical question and the available sample.

Step 2

Integrate the available information

Molecular results from the selected pathway are combined with the clinical and imaging context supplied by the treating team. Eight information domains; each contributes only when that information is available.

• 01Molecular & genomic. Variants, CNVs, structural changes, signatures, tumour fraction.
• 02Tumour biology. Clonality, evolution, pathways, microenvironment, vulnerabilities.
• 03Clinical context. Diagnosis, stage, prior lines, comorbidities, intent.
• 04Imaging integration. Radiology findings and change over time.
• 05Immune landscape. TME, immune signatures, biomarkers, predicted response.
• 06Treatment exposure. Therapies, dose, duration, response, toxicity.
• 07Patient factors. Age, organ function, symptoms, goals.
• 08Evidence ecosystem. Guidelines, approvals, trials and research — matched to the patient.

Step 3

Analyse across the framework

AI-assisted analysis runs across the applicable analytical layers. Not every layer runs for every case or every input: RNA-based analysis needs RNA data, growth dynamics need repeated measurements, and imaging integration needs imaging information.

Step 4

Produce structured outputs

The findings are organised into five report components.

1. 01Executive molecular summaryDistinguish source data from interpretation.
2. 02Molecular findingsState coverage, evidence strength and uncertainty.
3. 03Treatment optionsOptions to evaluate — never phrased as autonomous prescriptions.
4. 04Clinical-trial matchesA potential match is not eligibility or enrolment confirmation.
5. 05Longitudinal viewShow only updates supported by actual inputs and cadence.

See the report structure

Step 5

Clinical review and sign-off

Every Twin report is reviewed and signed by the treating oncologist, then taken to KPCIRC's internal Molecular Tumour Board. Clinical authority stays with the oncologist throughout.

1. 1

   Treating team

   Pathway and data

   The treating oncologist selects the testing pathway; clinical, molecular and imaging data are integrated.

2. 2

   OnKommon Twin

   21-layer analysis

   AI-assisted analysis across the applicable layers produces structured findings for clinician review.

3. 3

   OnKommon Twin

   Structured report

   Executive summary, molecular findings, treatment options to evaluate, trial matches and longitudinal view.

4. 4

   Treating oncologist

   Review and signature

   Every report is reviewed and signed by the treating oncologist.

5. 5

   KPCIRC

   Molecular Tumour Board

   The signed report is then taken to KPCIRC's internal Molecular Tumour Board (MTB).

6. 6

   Treating oncologist

   Decision and continuity

   Clinical authority stays with the oncologist. New evidence can prompt reassessment during the six-month journey.

Step 6

Review what changes over time

The Twin evolves with new evidence for six months. New findings are reviewed inside the workflow, and new evidence can prompt reassessment. At the end of month six, the evidence is reviewed and the next pathway is set — which may be one of the three Twin tracks.

1. 01 · Baseline — Day 0

   Integrate the data. Build the Twin.

2. 02 · During months 0–6

   Review new findings inside the workflow.

3. 03 · End of month 6

   Review the evidence. Set the next pathway.

4. 04 · After six months

   Twin tracks

   Track 12Track 47Track 118